Review Article - Journal of RNA and Genomics (2024) Volume 20, Issue 3
Genetic, demographic and virology study on active and mortality cases of COVID-19 across different countries of the world as at 12th October 17, 2022.
Joseph Opeyemi Tosin1*, Joseph Oyepata Simeon2, Makinde Adeola Victoria3, Sabastine Aliyu Zubairu4
1Department of Pharmacology and Toxicology, Federal University, Oye-Ekiti, Ekiti, Nigeria
2Department of Pharmacy, University College Hospital, Ibadan, Oyo, Nigeria
3Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, FUOYE, Nigeria
4Department of Pharmacology and Therapeutics, Gombe State University, Gombe, Nigeria
- Corresponding Author:
- Joseph Opeyemi Tosin
Department of Pharmacology and Toxicology, Federal University, Oye-Ekiti, Ekiti, Nigeria
E-mail: simeonjoseph50@gmail.com
Received: 10-Feb-2023, Manuscript No. RNAI-23-89231; Editor assigned: 13-Feb-2023, RNAI-23-89231 (PQ); Reviewed: 27-Feb-2023, QC No. RNAI-23-89231; Revised: 03-May-2024, Manuscript No. RNAI-23-89231 (R); Published: 10-May-2024, DOI:10.35841/2591-7781.20.3.190
Citation: Tosin JO, Simeon JO, Zubairu SA. Genetic, demographic and virology study on active and mortality cases of COVID-19 across different countries of the world as at 12th October 17, 2022. J RNA Genomics. 2024;20(3):1-9.
Abstract
Introduction/aim: Since the first case of infection with a new Coronavirus was detected in China in December 2019, SARS-CoV-2 has killed more than 5 million people and infected hundreds of millions of others. It has since spread to almost every country. This project’s goal is to conduct a study on COVID-19 death cases and current cases around the world as of October 12, 2022.
Materials and methods: The United Nations geoscheme provided data for 132 nations and regions around the globe. After compiling the findings, they were compared to those discovered for the USA.
Results: The majority of the American continent has close active case and death values to those of the USA when considering that country as a comparism point. The mortality value in the majority of American nations is higher than the active case value. Some European nations have incidence values that are significantly greater than those of the USA. Additionally, the majority of European nations have a greater active case value than a death value. African and Asian nations are less valuable. Africa’s worth is the lowest of the two.
Conclusion: Genetic variation may have played a role in infectability and mortality of COVID-19 virus. Further study need to be done to determine the significance of various contributing factor that may be a lead to development of more robust vaccine now and in the future.
Keywords
Africa, USA, COVID-19, America, Nigeria, Europe, Continent
Introduction
Genetic mutations or viral recombination may occur during genome replication [1-4]. An assemblage of genetically different viral strains with a common ancestor is referred to as a lineage [5,6]. One or more mutations in a particular strain of the SARS-CoV-2 virus distinguish it from other varieties. When the genetic material of two distinct variations is joined, a recombinant is created [7]. Throughout this pandemic, many SARS-CoV-2 mutations have been discovered globally and in the United States [8,9]. In order to enlighten local outbreak investigations and comprehend national trends, scientists analyze the genetic differences between viruses to uncover variants (including recombinants) and how they are related to one another [10-14].
The United States has 16% of the pandemic’s cases while having only 5% of the world’s population [15]. Many have assumed and conjectured that Africa will be the area most severely afflicted [16-19]. Even while it appears that this is not the case, there is still a great deal of worry and apprehension over the likelihood of a fresh outbreak with African origins. The Coronavirus family of viruses can cause respiratory illnesses in people [20-23]. The term “Coronas” refers to the spikes that cover the surface of the virus and look like crowns [24]. The common cold, Middle Eastern Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) are a few examples of Coronaviruses that can infect people [25]. A brand new strain of the Coronavirus known as COVID-19 was first identified in Wuhan, China, in December 2019 [26-29]. A recent variety from South Africa is called the omicron variant. Compared to the original virus that causes COVID-19 and the delta variation, it spreads more quickly and easily [30-33]. Even if individuals have had vaccinations or are asymptomatic, the CDC anticipates that anyone with an omicron infection, like the original, can spread the virus to others. People who have the omicron form of the virus may exhibit symptoms similar to those of earlier variants [34,35]. Age, other medical conditions, prior infection history and COVID-19 vaccination status can all have an impact on the presence and severity of symptoms [36].
Omicron infections often cause a milder sickness than early infections do. Omicron may cause relatively minor disease, but some people may still experience major illness, need hospitalization, and pass away from the infection brought on by this variant [37-39]. Even if just a tiny portion of patients with omicron infection require hospitalization, the huge number of cases could overwhelm the healthcare system, which is why it’s imperative to take preventative steps [40-43].
Numerous studies have examined the characteristics, nature and power of the virus; however, controlling and advancing the trend will also profit from monitoring the most recent information in real time [44-46]. The objective of this study is to conduct an update study on COVID-19 death cases and active cases worldwide as of October 12, 2022.
Literature Review
Methodology
132 nations from different continents and parts of the world were selected for this study. Information was obtained from the United Nations geoscheme. The information gathered on active and fatal cases up to October 12, 2022, per 100,000 persons for these countries were assessed and the results were directly compared to that gathered for the USA. Given that it has one of the greatest healthcare systems and the highest COVID-19 case rates across nations with comparable sized populations, the USA was employed as a Comparism Factor (CF) or Oyepata Factor (OF).
Statistical analysis
In this study, markers such as total cases and total deaths per 1,000,000 people were compared to US values. To compare the proportions of all the variables, the Chi-square test and bivariate analysis were also utilized. In summarizing this study, country observations are scaled to compare two nations that are otherwise comparable. Therefore, rate ratios below one suggest that lower levels of a certain trait are linked to lower rates of infection or mortality, and vice versa.
Results
The majority of the American continent has close active case and death values to those of the USA when considering that country as a comparison point. The mortality value in the majority of American nations is higher than the active case value. Some European nations have incidence values that are significantly greater than those of the USA. Additionally, the majority of European nations have a greater active case value than a death value. African and Asian nations are less valuable. Africa is the region with the lowest value (Table 1).
S/N | Country, other | Total cases | Total deaths | Active cases | Active cases/1 M pop (A) | A/5103 (OF1) | Deaths/1M pop (B) | B/3247 (OF2) |
---|---|---|---|---|---|---|---|---|
1 | USA | 98,572,011 | 10,87,976 | 17,10,125 | 5,103 | 1.00 | 3,247 | 1.00 |
2 | India | 44,616,394 | 5,28,822 | 27,374 | 19 | 0.00 | 375 | 0.12 |
3 | France | 35,875,626 | 1,55,535 | 9,02,207 | 13,753 | 2.70 | 2,371 | 0.73 |
4 | Brazil | 34,766,204 | 6,86,928 | 1,53,158 | 709 | 0.14 | 3,180 | 0.98 |
5 | Germany | 34,121,168 | 1,50,720 | 12,69,348 | 15,041 | 2.95 | 1,786 | 0.55 |
6 | S. Korea | 24,995,246 | 28,708 | 4,30,215 | 8,375 | 1.64 | 559 | 0.17 |
7 | UK | 23,735,273 | 1,90,888 | 1,50,251 | 2,187 | 0.43 | 2,779 | 0.86 |
8 | Italy | 22,896,742 | 1,77,650 | 5,20,919 | 8,644 | 1.69 | 2,948 | 0.91 |
9 | Japan | 21,564,995 | 45,538 | 10,85,461 | 8,642 | 1.69 | 363 | 0.11 |
10 | Russia | 21,232,963 | 3,88,404 | 3,74,007 | 2,560 | 0.50 | 2,659 | 0.82 |
11 | Turkey | 16,896,522 | 1,01,179 | 6,494 | 75 | 0.01 | 1,171 | 0.36 |
12 | Spain | 13,441,941 | 1,14,468 | 84,894 | 1,814 | 0.36 | 2,446 | 0.75 |
13 | Vietnam | 11,488,685 | 43,154 | 8,48,395 | 8,542 | 1.67 | 434 | 0.13 |
14 | Australia | 10,278,831 | 15,383 | 46,548 | 1,779 | 0.35 | 588 | 0.18 |
15 | Argentina | 97,13,594 | 1,29,958 | 9,656 | 209 | 0.04 | 2,817 | 0.87 |
16 | Netherlands | 84,65,022 | 22,702 | 65,973 | 3,831 | 0.75 | 1,318 | 0.41 |
17 | Iran | 75,52,812 | 1,44,498 | 80,162 | 927 | 0.18 | 1,672 | 0.51 |
18 | Mexico | 70,97,264 | 3,30,208 | 3,98,193 | 3,016 | 0.59 | 2,501 | 0.77 |
19 | Taiwan | 69,45,018 | 11,620 | 8,54,658 | 35,738 | 7.00 | 486 | 0.15 |
20 | Indonesia | 64,48,220 | 1,58,235 | 16,392 | 59 | 0.01 | 565 | 0.17 |
21 | Poland | 63,18,840 | 1,17,801 | 8,65,099 | 22,915 | 4.49 | 3,120 | 0.96 |
22 | Colombia | 63,08,087 | 1,41,807 | 30,465 | 585 | 0.11 | 2,721 | 0.84 |
23 | Portugal | 55,01,103 | 25,075 | 57,982 | 5,724 | 1.12 | 2,475 | 0.76 |
24 | Austria | 52,73,660 | 20,857 | 1,39,503 | 15,291 | 3.00 | 2,286 | 0.70 |
25 | Ukraine | 51,77,217 | 1,09,206 | 44,137 | 1,023 | 0.20 | 2,532 | 0.78 |
26 | Greece | 49,75,067 | 33,200 | 31,358 | 3,042 | 0.60 | 3,221 | 0.99 |
27 | Malaysia | 48,56,217 | 36,403 | 22,167 | 666 | 0.13 | 1,093 | 0.34 |
28 | DPRK | 47,72,813 | 74 | 0 | 0 | 0.00 | 3 | 0.00 |
29 | Thailand | 46,85,047 | 32,829 | 4,943 | 70 | 0.01 | 468 | 0.14 |
30 | Israel | 46,69,749 | 11,710 | 3,762 | 403 | 0.08 | 1,256 | 0.39 |
31 | Chile | 46,56,842 | 61,345 | 12,799 | 657 | 0.13 | 3,148 | 0.97 |
32 | Belgium | 45,75,519 | 32,746 | 73,112 | 6,247 | 1.22 | 2,798 | 0.86 |
33 | Canada | 42,70,891 | 45,394 | 65,288 | 1,696 | 0.33 | 1,179 | 0.36 |
34 | Peru | 41,48,691 | 2,16,788 | 5,573 | 164 | 0.03 | 6,373 | 1.96 |
35 | Switzerland | 41,44,447 | 14,203 | 93,173 | 10,590 | 2.08 | 1,614 | 0.50 |
36 | Czechia | 41,31,060 | 41,281 | 20,945 | 1,948 | 0.38 | 3,839 | 1.18 |
37 | South Africa | 40,21,386 | 1,02,194 | 6,686 | 110 | 0.02 | 1,675 | 0.52 |
38 | Philippines | 39,71,455 | 63,329 | 25,004 | 221 | 0.04 | 561 | 0.17 |
39 | Romania | 32,77,020 | 67,097 | 14,099 | 744 | 0.15 | 3,541 | 1.09 |
40 | Denmark | 31,22,154 | 7,151 | 13,505 | 2,313 | 0.45 | 1,225 | 0.38 |
41 | Sweden | 26,01,153 | 20,243 | 25,503 | 2,490 | 0.49 | 1,976 | 0.61 |
42 | Iraq | 24,60,868 | 25,356 | 464 | 11 | 0.00 | 600 | 0.18 |
43 | Serbia | 23,81,680 | 17,099 | 36,009 | 4,159 | 0.82 | 1,975 | 0.61 |
44 | Hungary | 21,07,907 | 47,576 | 35,039 | 3,648 | 0.71 | 4,953 | 1.53 |
45 | Bangladesh | 20,30,550 | 29,386 | 29,961 | 178 | 0.03 | 174 | 0.05 |
46 | Singapore | 19,57,916 | 1,632 | 86,783 | 14,574 | 2.86 | 274 | 0.08 |
47 | Slovakia | 18,47,728 | 20,485 | 5,702 | 1,043 | 0.20 | 3,748 | 1.15 |
48 | Hong Kong | 18,11,344 | 10,237 | 2,18,915 | 28,673 | 5.62 | 1,341 | 0.41 |
49 | New Zealand | 18,00,602 | 3,013 | 10,227 | 2,045 | 0.40 | 602 | 0.19 |
50 | Georgia | 17,80,691 | 16,900 | 1,26,498 | 31,849 | 6.24 | 4,255 | 1.31 |
51 | Jordan | 17,46,997 | 14,122 | 1,868 | 179 | 0.04 | 1,354 | 0.42 |
52 | Ireland | 16,66,048 | 7,922 | 6,282 | 1,241 | 0.24 | 1,565 | 0.48 |
53 | Pakistan | 15,73,115 | 30,620 | 3,806 | 17 | 0.00 | 133 | 0.04 |
54 | Norway | 14,63,093 | 4,121 | 1,180 | 214 | 0.04 | 747 | 0.23 |
55 | Kazakhstan | 13,94,028 | 13,692 | 970 | 50 | 0.01 | 710 | 0.22 |
56 | Finland | 13,12,634 | 6,149 | 26,614 | 4,786 | 0.94 | 1,106 | 0.34 |
57 | Bulgaria | 12,66,241 | 37,758 | 11,475 | 1,680 | 0.33 | 5,528 | 1.70 |
58 | Morocco | 12,65,115 | 16,278 | 125 | 3 | 0.00 | 429 | 0.13 |
59 | Lithuania | 12,58,521 | 9,347 | 18,283 | 6,935 | 1.36 | 3,546 | 1.09 |
60 | Croatia | 12,38,556 | 16,986 | 4,045 | 999 | 0.2 | 4,196 | 1.29 |
61 | Lebanon | 12,16,638 | 10,684 | 1,18,367 | 17,520 | 3.43 | 1,581 | 0.49 |
62 | Slovenia | 12,06,990 | 6,842 | 35,134 | 16,895 | 3.31 | 3,290 | 1.01 |
63 | Guatemala | 11,29,542 | 19,836 | 158 | 8 | 0.00 | 1,063 | 0.33 |
64 | Cuba | 11,11,238 | 8,530 | 78 | 7 | 0.00 | 754 | 0.23 |
65 | Bolivia | 11,08,702 | 22,237 | 29,369 | 2,440 | 0.48 | 1,848 | 0.57 |
66 | Costa Rica | 10,72,807 | 8,913 | 2,03,183 | 39,076 | 7.66 | 1,714 | 0.53 |
67 | UAE | 10,31,500 | 2,346 | 18,613 | 1,832 | 0.36 | 231 | 0.07 |
68 | Ecuador | 10,06,070 | 35,900 | 2,442 | 134 | 0.03 | 1,967 | 0.61 |
69 | Nepal | 9,99,946 | 12,018 | 575 | 19 | 0.00 | 396 | 0.12 |
70 | Belarus | 9,94,037 | 7,118 | 1,327 | 141 | 0.03 | 754 | 0.23 |
71 | Panama | 9,88,280 | 8,505 | 872 | 195 | 0.04 | 1,903 | 0.59 |
72 | Uruguay | 9,86,446 | 7,495 | 996 | 284 | 0.06 | 2,141 | 0.66 |
73 | Mongolia | 9,83,610 | 2,179 | 884 | 260 | 0.05 | 641 | 0.20 |
74 | Azerbaijan | 8,22,278 | 9,931 | 526 | 51 | 0.01 | 960 | 0.30 |
75 | Saudi Arabia | 8,18,033 | 9,372 | 3,849 | 107 | 0.02 | 260 | 0.08 |
76 | Paraguay | 7,17,039 | 19,595 | 83 | 11 | 0.00 | 2,673 | 0.82 |
77 | Bahrain | 6,83,773 | 1,521 | 2,454 | 1,337 | 0.26 | 828 | 0.26 |
78 | Sri Lanka | 6,70,884 | 16,768 | 107 | 5 | 0.00 | 776 | 0.24 |
79 | Kuwait | 6,60,667 | 2,564 | 990 | 224 | 0.04 | 581 | 0.18 |
80 | Myanmar | 6,25,497 | 19,464 | 8,135 | 147 | 0.03 | 352 | 0.11 |
81 | Palestine | 6,20,757 | 5,404 | 439 | 82 | 0.02 | 1,006 | 0.31 |
82 | Estonia | 6,04,380 | 2,713 | 76,677 | 57,714 | 11.31 | 2,042 | 0.63 |
83 | Cyprus | 5,90,783 | 1,187 | 8,402 | 6,846 | 1.34 | 967 | 0.30 |
84 | Moldova | 5,90,752 | 11,858 | 74,752 | 18,629 | 3.65 | 2,955 | 0.91 |
85 | Venezuela | 5,44,966 | 5,818 | 476 | 17 | 0.00 | 206 | 0.06 |
86 | Egypt | 5,15,645 | 24,613 | 48,850 | 458 | 0.09 | 231 | 0.07 |
87 | Libya | 5,07,010 | 6,437 | 45 | 6 | 0.00 | 909 | 0.28 |
88 | Ethiopia | 4,93,698 | 7,572 | 14,121 | 116 | 0.02 | 62 | 0.02 |
89 | Qatar | 4,59,122 | 682 | 3,011 | 1,072 | 0.21 | 243 | 0.07 |
90 | Armenia | 4,44,482 | 8,700 | 2,971 | 998 | 0.20 | 2,924 | 0.90 |
91 | Bosnia and Herzegovina | 3,99,227 | 16,155 | 6,220 | 1,923 | 0.38 | 4,994 | 1.54 |
92 | Oman | 3,98,424 | 4,260 | 9,495 | 1,758 | 0.34 | 789 | 0.24 |
93 | North Macedonia | 3,43,391 | 9,548 | 339 | 163 | 0.03 | 4,583 | 1.41 |
94 | Kenya | 3,38,506 | 5,678 | 18 | 0 | 0.00 | 101 | 0.03 |
95 | Zambia | 3,33,624 | 4,017 | 63 | 3 | 0.00 | 205 | 0.06 |
96 | Albania | 3,32,503 | 3,589 | 1,686 | 587 | 0.12 | 1,250 | 0.38 |
97 | Botswana | 3,26,344 | 2,790 | 599 | 244 | 0.05 | 1,134 | 0.35 |
98 | Algeria | 2,70,713 | 6,881 | 81,489 | 1,785 | 0.35 | 151 | 0.05 |
99 | Nigeria | 2,65,816 | 3,155 | 3,618 | 17 | 0.00 | 14 | 0.00 |
100 | Zimbabwe | 2,57,749 | 5,604 | 408 | 27 | 0.01 | 365 | 0.11 |
101 | China | 2,54,066 | 5,226 | 4,104 | 3 | 0.00 | 4 | 0.00 |
102 | Mozambique | 2,30,312 | 2,222 | 126 | 4 | 0.00 | 67 | 0.02 |
103 | Brunei | 2,29,665 | 225 | 7,300 | 16,332 | 3.20 | 503 | 0.15 |
104 | Rwanda | 1,32,518 | 1,467 | 24 | 2 | 0.00 | 107 | 0.03 |
105 | Cameroon | 1,21,652 | 1,935 | 1,101 | 39 | 0.01 | 69 | 0.02 |
106 | Malta | 1,14,910 | 806 | 701 | 1,578 | 0.31 | 1,814 | 0.56 |
107 | Angola | 1,03,131 | 1,917 | 59 | 2 | 0.00 | 54 | 0.02 |
108 | Barbados | 1,02,580 | 560 | 208 | 722 | 0.14 | 1,943 | 0.60 |
109 | French Guiana | 94,073 | 410 | 82,409 | 2,60,576 | 51.06 | 1,296 | 0.40 |
110 | DRC | 92,934 | 1,443 | 7,970 | 83 | 0.02 | 15 | 0.00 |
111 | Senegal | 88,506 | 1,968 | 121 | 7 | 0.00 | 111 | 0.03 |
112 | Malawi | 88,047 | 2,682 | 399 | 20 | 0.00 | 132 | 0.04 |
113 | Ivory Coast | 87,438 | 826 | 46 | 2 | 0.00 | 30 | 0.01 |
114 | Fiji | 68,244 | 878 | 1,061 | 1,164 | 0.23 | 964 | 0.30 |
115 | Madagascar | 66,687 | 1,410 | 10 | 0 | 0.00 | 48 | 0.01 |
116 | Sudan | 63,344 | 4,962 | 945 | 20 | 0.00 | 107 | 0.03 |
117 | Mauritania | 62,920 | 995 | 106 | 22 | 0.00 | 202 | 0.06 |
118 | Cabo Verde | 62,389 | 410 | 63 | 111 | 0.02 | 720 | 0.22 |
119 | Bhutan | 62,200 | 21 | 615 | 778 | 0.15 | 27 | 0.01 |
120 | Syria | 57,325 | 3,163 | 21 | 1 | 0.00 | 171 | 0.05 |
121 | Gabon | 48,713 | 306 | 100 | 43 | 0.01 | 130 | 0.04 |
122 | Andorra | 46,275 | 155 | 67 | 864 | 0.17 | 1,999 | 0.62 |
123 | Papua New Guinea | 45,133 | 668 | 483 | 52 | 0.01 | 72 | 0.02 |
124 | Mauritius | 40,519 | 1,027 | 635 | 497 | 0.10 | 805 | 0.25 |
125 | Somalia | 27,223 | 1,361 | 12,680 | 750 | 0.15 | 81 | 0.02 |
126 | Burkina Faso | 21,631 | 387 | 101 | 5 | 0.00 | 17 | 0.01 |
127 | South Sudan | 17,823 | 138 | 350 | 30 | 0.01 | 12 | 0.00 |
128 | Tajikistan | 17,786 | 125 | 397 | 40 | 0.01 | 12 | 0.00 |
129 | Equatorial Guinea | 17,040 | 183 | 150 | 99 | 0.02 | 121 | 0.04 |
130 | Monaco | 14,717 | 63 | 63 | 1,580 | 0.31 | 1,580 | 0.49 |
131 | Gambia | 12,508 | 372 | 108 | 42 | 0.01 | 145 | 0.04 |
132 | Niger | 9,931 | 312 | 729 | 28 | 0.01 | 12 | 0.00 |
Table 1. Cases and death of COVID-19.
Key: Data used were obtained from WHO/World meter’s as at 17th February, 2022. Figures obtained for USA were used in determining the Comparism Factor (CF) or oyepata factor which is a ratio of figure obtained to that of a particular country population divided by that of the USA (Figures 1 and 2).
Values of CF1 or OF1 and CF2 or OF2 represent case/incidence and mortality index.
• Factor of more than 1=Very high infection and mortality
index.
• Factor of approximately 1=High infection and mortality
index.
• Factor of ≤ 1 but ≥ 0.5=Moderately high infection and
mortality index.
• Factor of ≤ 0.5 but ≥ 0.1=Low infection and mortality
index.
• Factor of <0.1=Very low infection, mortality and recovery
index.
Discussion
The pandemic is still being controlled over the globe. COVID-19 mortality is frequently estimated using a range of indicators. These numbers fluctuate over time and by region, based on the number of tests performed, the efficiency of the healthcare system, the therapies available, the length of time since the outbreak started, and the age, sex and general health of the population [47-50]. The mortality rate is determined by dividing the overall death rate for a certain demographic group by the group’s overall population. As a result, the death rate in a particular group reflects both the prevalence and the severity of the disease. There is a strong correlation between age and death rates, with younger people experiencing relatively low rates and elderly people experiencing very high rates.
The results show that the majority of American countries have about the same numbers of current cases and fatalities as the USA. The mortality value in the majority of American nations is higher than the active case value. Some European nations have incidence values that are significantly greater than those of the USA. Additionally, the majority of European nations have a greater active case value than a death value. African and Asian nations are less valuable. Africa’s worth is the lowest of the two. Genetic, environmental, personal health state, vaccine response, and seasonal variation could all have a role in this distribution’s variation [51-56].
Despite having one of the highest standards of life and most modern technology, the USA is nonetheless one of the most severely affected nations. The virus has a comparatively small impact on the poor and underdeveloped nations of Africa. It was anticipated that the virus would have a greater impact in Africa, but the exact opposite has happened. Therefore, it is plausible that because of their socioeconomic, genetic or preexposure backgrounds, nations like Haiti and Africa may have built a more potent defense to the virus.
The evidence now available indicates that infections in Africa, a region that is regarded as undeveloped do not have significant medical consequences and when contracted, people tend to recover more rapidly with a lower risk of complications and fatality [57-60].
As was already mentioned, Africans live in densely populated areas, which are clearly distinct from the vast majority of western countries, which rely on a solitary system [61]. The majority of people in Africa may therefore have been exposed to the virus without being aware of it or displaying any serious symptoms. According to some analysts, these events could cause Africa to resemble a cemetery [62-67]. Many experts throughout the world are baffled by the causes of this pleasantly unexpected catastrophe. According to studies, African children’s immune systems tend to develop more quickly and robustly than those of Dutch children due to their poor health and surroundings [68-71]. When exposed to the same allergy or infection later on, exposure to the pathogenic organism may have boosted children’s immune systems and protected them from catching certain infectious diseases and allergies [72,73]. Additional supporting data for this claim comes from statistics and a comparison factor from Haiti. Haiti is currently both the least developed nation in the world and the poorest nation in all of Latin America and the Caribbean. Their low rates of disease and mortality have little to no impact on the importance of the comparism factor. A higher immune reaction to the same or a comparable illness may have resulted from early or childhood exposure to particular diseases in developing countries.
Several African nations are thus both susceptible to the Coronavirus and possibly more equipped to defend themselves from it. African immigration to or inundation of other continents, which has allowed for the establishment of cross human immunity, may be connected to higher vaccination rates and lower infection mortality globally. The most effective immunization must therefore be created using an antibody or serum from an African source.
Conclusion
Genetic variation may have played a role in infectability and mortality of COVID-19 virus, resulting in Africa, with the least vaccination and medical facility, have the least infection and mortality value. Further study need to be done to determine the significance of various contributing factor that may be a lead to development of more robust vaccine now and in the future.
Acknowledgements
The contributors to the data collection and analysis are all thanked by the authors. Special thanks go to the WHO and the United Nations geoscheme for facilitating information access.
Conflicts of Interest
There is no conflict of interest.
References
- Fan Y, Zhao K, Shi ZL, et al. Bat Coronaviruses in China. Viruses. 2019;11(3):210-23.
[Crossref] [Google Scholar] [PubMed]
- Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: A rapid review. Cochrane Database Syst Rev. 2020;9(9):CD013574.
[Crossref] [Google Scholar] [PubMed]
- Joseph OS, Joseph OT. Hepatoprotective activity of ethanol stems extract of Homalium letestui against thioacetamide induced liver injury. Nigerian J Pharm. 2018;52(1):67-74.
- Joseph OS, Jude EO, Joseph OT. Hepatoprotective activity of extract of Homalium letestui stem against carbon tetrachloride induced liver injury. Adv Herb Med. 2018;4(4):1-11.
- Joseph SO, Okokon JE and Joseph OT. Effect of ethanol stem extract of Homalium letestui on gentamicin induced kidney injury in rat. Adv Herb Med. 2018;4(2):51-64.
- Simeon JO, Builders M, Haruna WC, et al. Effect of administration ethanol leaf extract of Terminalia chebula on liver of Wistar rat. Int J Res Sci Innov. 2019;91-7.
- Sabastine AZ, Musa TL, Joseph OS, et al. Histological study of effect of ethanol stem extracts of Homalium letestui in paracetamol induced injury in albino rat, using various staining techniques. Am J Biomed Sci Res. 2019;4(2):82-9.
- Joseph OS, Builders M, Joseph OT, et al. Toxicity study of ethanol leaf extract of Ocimum canum on heart and lipid profile of Wistar rats. Int J Curr Adv Res. 2019;8(5):18800-3.
- Islam MA. Prevalence and characteristics of fever in adult and paediatric patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.
[Crossref] [Google Scholar] [PubMed]
- Islam MA. Prevalence of headache in patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis of 14,275 patients. Front Neurol. 2020;11:562634.
[Crossref] [Google Scholar] [PubMed]
- Joseph OS, Builders M, Joseph OT, et al. Sub-acute toxicity study of ethanol leaf extract of Ocimum canum on liver of Wistar rats. Int J Res Sci Innov. 2019;364-9.
- Modupe IB, SOyepata SJ, Akpobome RV. Effect of Parkia biglobosa extract on open skin wound healing in dexamethasone induced hyperglycaemia and histological assessment in rats. Afr J Pharm Pharmacol. 2019;13(8):84-9.
- Builder MI, Anzaku SA, Joseph SO. Effectiveness of intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine against malaria in northern Nigeria. Int J Recent Sci Res. 2019;10(05):32295-9.
- Joseph OS, Builders M, Joseph OT, et al. Sub-acute toxicity study of ethanol leaf extract of Ocimum canum on brain, lungs, stomach and spleen of Wistar rats. Afr J Pharm Res Dev. 2019;11(1):35-42.
- Joseph OS, Builders M, Emem EU, et al. Effect of ethanol leaf extract of Cassia angustifolia extract on liver of Wistar rats. Glob Sci J. 2019;8(9):1112-20.
- Builder MI, Joseph SO, Olugbemi TO, et al. Toxicity studies of extract of African mistletoe: Agelanthus Dodoneifolius Polh and Wiens in rats. Nigeria Biomed J. 2020;113-30.
- Wu X, Nethery RC, Sabath MB, et al. Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis. Sci Adv. 2020;6(45):342-55.
[Crossref] [Google Scholar] [PubMed]
- Oyepata JS. The earth: A lost planet from another universe. Int J Multidiscip Res Anal. 2021;4(12):1795-7.
- Simeon JO, Tosin JO, Adegbenga AD. The relative global consequences of cumulative distribution of COVID-19, using the USA as comparism factor and cumulative COVID-19 data of 31st October 2021. Int J Multidiscip Res Anal. 2021;1906-17.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13.
[Crossref] [Google Scholar] [PubMed]
- Solomon IP, Oyebadejo SA, Ukpo EM, et al. Changes in serum electrolyte, creatinine and urea of fresh Citrus limon juice administered to growing rabbits (Oryctolagus cuniculus). Int J Agric Sci Res. 2015;4(8):180-3.
- Solomon IP, Oyebadejo SA, Ukpo EM, et al. Effect of fresh Citrus limon juice on liver histomorphology of growing rabbits (Oryctolagus cuniculus). Scholars J Agric Vet Sci. 2015;2(5):347-51.
- Aprioku JS, Joseph OS, Obianime AW. Quantification of antinociceptive and anti-inflammatory potentials of different Ocimum gratissimum Linn. leaf extracts in male whistar albino rats. Eur J Med Plant. 2016;17:1-8.
- Okokon JE, Simeon JO, Umoh EE. Nephroprotective activity of Homalium letestui stem extract against paracetamol induced kidney injury. J Exp Integr Med. 2016;6(1):38.
- Okokon JE, Joseph OS, Umoh EE. Hepatoprotective activity of Homalium letestui stem extract against paracetamol liver injury. Avicenna J Phytomed. 2016;13(4):87-92.
- Timothy SY, Wazis CH, Midala TA, et al. Evaluation of anti-diarrhoeal activity of different bark extracts of Faidherbia albida (Delile) A (Chav) in albino rats. Bima J Sci Technol. 2017;1(2):122-30.
- Oluwakanyesola AS, Joseph OS, Jacob A, et al. Sub-acute haematological toxicity study of safi® blood purifier on wister rats. Niger J Pharm. 2018;52(20).
- Tosin JO, Wolfe OA, Iyeopu SM, et al. Clinical study on the effect of Moringa oleifera on serum level of glucose and triglyceride in subjects taken tenofovir, lamivudine and efavirenz combination regimen. Eur Sci J. 2019;15(21):280-93.
- Simeon JO, Modupe B, Haruna WC, et al. Histological study of effect of ethanol stem extracts of Homalium letestui on thioacetamide induced injury in albino rat, using various staining techniques. Int J Res Sci Innov. 2019;4(2):77-85.
[Crossref]
- Samson AO, Joseph OS, Samson OA, et al. Effect of Citrus limon juice and tamoxifen on the oxidative activities of MCT-7 cell induced breast cancer in Sprague dawley Rats. Saudi J Biomed Res. 2019;8(7):76-92.
- Simeon JS, Builders M, Deborah IR, et al. Sub-acute toxicity study of ethanol leaf extract of Terminalia chebula on brain, stomach and spleen of wister rats. Am J Biomed Sci Res. 2019;3(3):277-82.
[Crossref]
- Oyebadejo SA, Joseph OS, Adesite SO, et al. Effect of Citrus limon juice and tamoxifen on the tumour growth mass indices, cell proliferation, cell viability and cytogenetic (mitotic index) of Sprague dawley rats induced MCF-7 breast cancer cells. Saudi J Biomed Res. 2019;4:216-25.
- Joseph OS, Builders M, Joseph OT, et al. Sub-acute toxicity study of ethanol leaf extract of Ocimum canum on the kidney of wistar rats. Afr J Pharm Res Dev. 2019;11(1):1-7.
- Joseph OS, Joseph OT, Musa TL, et al. Histological evaluation of the nephroprotective activity of the ethanol stem extracts of Homalium letestui in gentamicin induced albino rats injury, using various staining techniques. Glob Sci J. 2019;7(8):1065-87.
[Crossref]
- Joseph OS, Builders M, Emem EU, et al. Effect of ethanol leaf extract of Cassia angustifolia extract on kidney of wister Rats. Glob Sci J. 2019;7(10):106-22.
- Haruna WC, Simeon JO, Builders M, et al. Effect of ethanol leaf extract of Cassia angustifolia extract on heart and lipid profile of wister rats. Afr J Pharm Res Dev. 12(1):1-8.
- Haruna WC, Builders M, Simeon JO, et al. Toxicological study of the effect of ethanol leaf extract of Pterocarpus santalinus extract on liver of wister rats. Niger Biomed Sci J. 2020;17-29.
- Wazis CH, Joseph OS, Modupe B, et al. Effect of ethanol leaf extract of Pterocarpus santalinus extract on kidney of wister rats. Niger Biomed Sci J. 2020;17(1):35-47.
- Builders MI, Joseph SO, Bassi PU. A survey of wound care practices by nurses in a clinical setting. Int J Healthcare Med Sci. 2020;6(5):74-81.
- Joseph OS, Builders M, Joseph OT. Effect of caffeine on diazepam induced sedation and hypnosis in wister rat. Glob Sci J. 2020;8(9):451-66.
- Joseph OS, Builders M, Joseph OT, et al. Assessing differential impacts of COVID-19 on African countries: A comparative study. Int J Res Innov Appl Sci. 2020;5(5):197-203.
- Simeon JO, Lubo MT, Tosin JO, et al. The dynamics of differential impacts of COVID-19 on African countries compared to other parts of the world. Int J Multidisc Res Anal. 2020;3(11):185-98.
- Builders MI, Simeon JO, Ogundeko TO, et al. Antimalarial drugs and COVID-19. Sumerianz J Med Healthc. 2020;3(12):111-6.
- Zubairu SA, Simeon JO, Tosin JO. Effect of ethanol leaf extract of Terminalia chebula extract on kidney of wister rats. Glob Sci J. 2021;9(2):514-26.
- Joseph OS , Builders M , Joseph OT, et al. Effect of the demographic of COVID-19 on different countries; using the USA for comparism. Int J Multidisc Res Anal. 2021;4(2):193-203.
- Joseph SO, Opeyemi JT. Effect of clinical study of Moringa oleifera on body mass index, low density lipoprotein and triglyceride level in patients on tenofovir/lamivudine/efavirenz combination therapy. Adv Herb Med. 2020;6(1):14-27.
- Zubairu SA, Festus OA, Simeon JO, et al. Effect of Anacardium occidentale fruit juice extract on haematological parameters and spleen of paracetamol induced injury in albino rats. Glob Sci J. 2021;9(7):1640-54.
- Saniasiaya J, Islam MA. Prevalence of olfactory dysfunction in Coronavirus Disease-2019 (COVID-19): A meta-analysis of 27,492 patients. Laryngoscope. 2021;131(4):865-78.
[Crossref] [Google Scholar] [PubMed]
- Sabastine AZ, Joseph OS, Joseph OS, et al. Effect of cashew apple juice (Anacardium occidentale L.) on hematology and spleen of gentamicin induced injury in albino rats. Glob Sci J. 2021;9(7):3686-98.
- Tosin JO, Zubairu SA, Simeon JO. Clinical effect of Moringa oleifera on body mass index, triglyceride and high density lipoprotein in subjects taken tenofovir combination regimen. Eur J Biol Med Sci Res. 2021;9(4):6-19.
[Crossref]
- Smeon JO, Zubairu SA, Tosin JO. Global implication of differential impacts of COVID-19 on different countries using the USA as a comparism factor. J Nurs Health Sci. 2021;10(5):36-44.
- Simeon JO, Simeon JO, Zubairu SA, et al. Concomitant administration of ethanol leaf extract of Thymus vulgaris on diazepam induced sedation and hypnosis in wister rat. J Nurs Health Sci. 2021;16(5):4-9.
- Simeon JO, Zubairu SA, Tosin JO. Clinical evaluation of the potential benefits of taking Moringa oleifera on blood triglyceride and cholesterol level in patient taking Tenofovir/Lamivudine/Efavirenz (TLE) combination. J Pharm Sci Res. 2021;13(10):623-9.
- Zubairu SA, Simeon JO, Tosin JO. Analysis and understanding the progress, trend and consequences of COVID-19 pandemic over a seven days period across different countries of the world. Int J Adv Eng Manag. 2022;4(2):1588-98.
- Simeon JO, Tosin JO, Zubairu SA, et al. Toxicological evaluation of Lavandula stoechas on heart and blood of wistar rat. Int J Adv Eng Manag. 2022;4(4):1233-41.
[Crossref]
- Simeon JO, Zubairu SA, Tosin JO, et al. Update report and analysis on the global trends and progress of COVID-19 pandemic on 18th January, 2022 across different countries of the world. Int J Res Innov Appl Sci. 2022;3(4):58-66.
- Joseph OT, Olorunfemi AF, Sabastine AZ, et al. Understanding the cumulative distribution, implication and progress on COVID-19 pandemic as at 7th of February 2022 across different countries of the world: An update report. Int J Res Innov Soc Sci. 2022;3(4):691-699.
- Simeon JO, Tosin JO, Zubairu SA. Cumulative evaluation of demography and distribution of COVID-19 around the globe: An update report of COVID-19 until 17th February 2022. Int J Epidemiol Health Sci. 2022;3(6):e34.
- Domingo JL, Marques M, Rovira J. Influence of airborne transmission of SARS-CoV-2 on COVID-19 pandemic: A review. Environ Res. 2020;188:66-73.
[Crossref] [Google Scholar] [PubMed]
- Wang L, Wang Y, Ye D, et al. Review of the 2019 novel Coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948.
[Crossref] [Google Scholar] [PubMed]
- Oyepata JS, Simeon JO. The earth: An alien planet in another universe. Glob J Sci Front Res. 2022;22(1):55-7.
- Joseph OS, Sabastine AZ, Joseph OT, et al. An analysis of daily distributive effect of COVID-19 pandemic across the globe using the USA as a comparism factor: An update report of 17th of February, 2022.
- Simeon JO, Tosin JO, Zubairu SA. Virological and immunological consequences of COVID-19 pandemic distribution across different countries; a seven days update study. Int J Adv Eng Manag. 2022;4(8):871-83.
- Tosin JO, Simeon JO. Mathematical and demographic understanding on the effect COVID-19 across the country of the world; an update report of cases and death from 2nd to 8th of August, 2022. Int J Adv Eng Manag. 2022;4(8):891-903.
- Modupe BI, Simeon JO, Tosin JO. Toxicological study of ethanol extract of Lavandula stoechas on liver of wistar rat. Int J Adv Eng Manag. 2022;4(9):892-901.
- Modupe BI, Simeon JO, Oyepata JS, et al. Update report on comparism and analysis on the progress made in cases and death of COVID-19: A seven days study. Int J Adv Eng Manag. 2022;4(9):902-15.
- Simeon JO. UFOs and human: Understanding the relevance, purpose and humofunctional implication. Int J Res Publ Rev. 2022;3(9):1304-8.
- Builders Iretiola M, Joseph Oyepata S, et al. Toxicological study of ethanol extract of Lavandula stoechas on kidney of wistar rat. Int J Res Publ Rev. 2022;3(9):1290-8.
[Crossref]
- Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr. 2020;14(4):655-9.
[Crossref] [Google Scholar] [PubMed]
- Simeon JO, Tosin JO, Daniel MF, et al. COVID-19 cases and mortality report across countries of the world, using USA as a comparism factor: An update report 18th to 24th of August, 2022. Int J Res Publ Rev. 2022;3(9):1262-72.
- Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that is asymptomatic. Ann Int Med. 2021;174(9):1344-5.
[Crossref]
- Simeon JO, Tosin JO. Update report on virological and mortality distribution and implication of COVID-19 pandemic across the globe from 28th January to 3rd February 2022. Int J Epidemiol Health Sci. 2023;4:e47.
- Centers for Disease Control and prevention. Interim clinical guidance for management of patients with confirmed Coronavirus Disease (COVID-19). 2020.